Sandy Van Hemelryck

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 4

Top Topics

Hiv Infected Patients

Top Venues

Antiviral therapy

Molecular pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Sandy Van Hemelryck, Erika Van Landuyt, Veerle Hufkens, Simon Vanveggel
Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study. Antiviral therapy 29 (2) (2024)
Sandy Van Hemelryck, Erika Van Landuyt, Veerle Hufkens, Simon Vanveggel
Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study. Antiviral therapy 29 (2) (2024)
Sandy Van Hemelryck, Rani Wens, Hannelore van Poppel, Milou Luijks, Koosha Shahidi, Marcin Marczak, Ariane Kahnt, René Holm, Erik Mannaert, Peter Langguth
In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Injection in Rats. Pharmaceutics 13 (8) (2021)
An Van den Bergh, Sandy Van Hemelryck, Jan Bevernage, Achiel Van Peer, Marcus Brewster, Claire Mackie, Erik Mannaert
Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis. Molecular pharmaceutics 15 (7) (2018)